Antidepressants in chronic idiopathic urticaria

Allergy and Asthma Proceedings

Volumn 32, Issue 6, 2011, Pages 419-424

  Yasharpour, Michelle R ^a   Randhawa, Inderpal ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b MILLER CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; CIMETIDINE; DIPHENHYDRAMINE; DOXEPIN; EBASTINE; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROCORTISONE; HYDROXYZINE; IMMUNOGLOBULIN E; LORAZEPAM; MIRTAZAPINE; NALMEFENE; NALTREXONE; PAROXETINE; PLACEBO; PREGABALIN; RUPATADINE; SERTRALINE;

ANGIONEUROTIC EDEMA; ANXIETY DISORDER; APPLICATION SITE REACTION; ARTICLE; ATOPIC DERMATITIS; AUTOREGULATION; CHRONIC URTICARIA; CONTACT DERMATITIS; DECREASED APPETITE; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; FATIGUE; HEART ARRHYTHMIA; HUMAN; IDIOPATHIC DISEASE; IMMUNOGLOBULIN PRODUCTION; MENTAL DISEASE; NAUSEA; NERVE FIBER; NEURODERMATITIS; NUMMULAR DERMATITIS; PATHOPHYSIOLOGY; PHOTOSENSITIVITY; PREVALENCE; PRURITUS; PSORIASIS VULGARIS; SEDATION; SIDE EFFECT; URTICARIA; VOMITING;

ANTIDEPRESSIVE AGENTS; CHRONIC DISEASE; COMORBIDITY; HUMANS; URTICARIA;

EID: 84355167634     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2011.32.3475     Document Type: Article

References (40)

1. Fromer L. Treatment options for the relief of chronic idiopathic urticaria symptoms. South Med J 101:186-192, 2008.
2. Peroni A, Colato C, Schena D, et al. Urticarial lesions: If not urticaria, what else? The differential diagnosis of urticaria. J Am Acad Dermatol 62:541-555, 2010.
3. Baiardini I, Giardini A, Pasquali M, et al. Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. Allergy 58:621-623, 2003. (Pubitemid 36831317)
4. Khan DA. Chronic urticaria: Diagnosis and management. Allergy Asthma Proc 29:439-446, 2008.
5. Koo JY, and Pham CT. Psychodermatology. Practical guidelines on pharmacotherapy. Arch Dermatol 128:381-388, 1992.
6. Uguz F, Engin B, and Yilmaz E. Quality of life in patients with chronic idiopathic urticaria: The impact of Axis I and Axis II psychiatric disorders. Gen Hosp Psychiatry 30:453-457, 2008.
7. Delong LK, Culler SD, Saini SS, et al. Annual direct and indirect health care costs of chronic idiopathic urticaria: A cost analysis of 50 nonimmunosuppressed patients. Arch Dermatol 144:35-39, 2008. (Pubitemid 351159387)
8. O'Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 136:197-201, 1997. (Pubitemid 27062719)
9. Yosipovitch G, Greaves MW, and Schmelz M. Itch. Lancet. 361:690-694, 2003. (Pubitemid 36253608)
10. Teshima H, Nagata S, Kinara H, et al. Psychobiological studies on the onset of allergic disease. A Japanese approach. Advances 3:143-149, 1986.
11. Locala J. Current concepts in psychodermatology. Curr Psychiatr Rep 11:211-218, 2009.
12. Torresani C, Bellafiore S, and De Panfilis G. Chronic urticaria is usually associated with fibromyalgia syndrome. Acta Derm Venereol 89:389-392, 2009.
13. Meggs WJ. Neurogenic switching: A hypothesis for a mechanism for shifting the site of inflammation in allergy and chemical sensitivity. Environ Health Perspect 103:54-56, 1995.
14. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA2LEN/EDF/WAO guideline: Management of urticaria. Allergy 64:1427-1443, 2009.
15. Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult to treat urticaria. J Allergy Clin Immunol 125:676-682, 2010.
16. Asero R, and Tedeschi A. Emerging drugs for chronic urticaria. Expert Opin Emerg Drugs 11:265-274, 2006. (Pubitemid 43723308)
17. Champion RH, Robert SOB, Carpenter RG, et al. Urticaria and angioedema. Br J Dermatol 81:588, 1969.
18. Morgan M, and Khan DA. Therapeutic alternatives for chronic urticaria: An evidence based review, Part 1. Ann Allergy Asthma Immunol 100:403-311, 2008.
19. Morgan M, and Khan DA. Therapeutic alternatives for chronic urticaria: An evidence based review, Part 2. Ann Allergy Asthma Immunol 100:517-526, 2008. (Pubitemid 351829849)
20. Asero R, and Tedeschi A. Emerging drugs for chronic urticaria. Expert Opin Emerg Drugs 11:265-274, 2006. (Pubitemid 43723308)
21. Hashiro M, and Yamatodani Y. A combination therapy of psychotropic drugs and antihistamines or antiallergics in patients with chronic urticaria. J Dermatol Sci 11:209-313, 1996.
22. Gupta MA, and Gupta AK. The use of antidepressant drugs in dermatology. Eur Acad Dermatol Venereol 15:512-518, 2001.
23. Goldsobel AB, Rohr AS, Siegel SC, et al. Efficacy of doxepin in the treatment of chronic idiopathic urticaria. J. Allergy Clin Immunol 867-873, 1986. (Pubitemid 17194639)
24. Drake LA, and Millikan LE. The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Doxepin Study Group. Arch Dermatol 131:1403-1408, 1995.
25. Demling R, and DeSanti L. Topical doxepin significantly decreases itching and erythema in the chronically pruritic burn scar. Wounds Res www.woundsresearch.com/article/1747, 2003.
26. Duman EN, Kesim M, Kadioglu M, et al. Possible involvement of opiodergic and serotonergic mechanisms in antinociceptive effect of paroxetine in acute pain. J Pharmacol Sci 94:161-165, 2004. (Pubitemid 38405130)
27. Mayo MJ, Handem I, Saldana S, et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 45:666-674, 2007. (Pubitemid 46450618)
28. Krasowska D, Szymanek M, Schwartz RA, et al. Cutaneous effects of the most commonly used antidepressant medication, the selective serotonin reuptake inhibitors. J Am Acad Dermatol 56:848-853, 2007. (Pubitemid 46560997)
29. Leznof A, Binkley KE, Joffee RT, et al. Adverse cutaneous reactions associated with fluoxetine strategy for reintroduction of this drug in selected patients. J Clin Psychopharmacol 12: 355-357, 1992.
30. Monroe E. Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis. J Am Acad Dermatol 21:135-136, 1989. (Pubitemid 19171479)
31. Malekzad F, Arbabi M, Mohtasham N, et al. Efficacy of oral naltrexone on pruritus in atopic eczema: A double-blind, placebo-controlled study. J Eur Acad Dermatol Venereol 23:948-950, 2009.
32. Ständer S, Weisshaar E, and Luger TA. Neurophysiological and neurochemical basis of modern pruritus treatment. Exp Dermatol 17:161-169, 2008. (Pubitemid 351233860)
33. Bigliardi PL, Stammer H, Jost G, et al. Treatment of pruritus with topically applied opiate receptor antagonist. J Am Acad Dermatol 56:979-988, 2007. (Pubitemid 46720216)
34. Bigata X, Sais G, and Soler F. Severe chronic urticaria: Response to mirtazapine. J Am Acad Dermatol 53:916-917, 2005. (Pubitemid 41501404)
35. Antilla SA, and Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 7:249-264, 2001. (Pubitemid 34016084)
36. Yesudian PD, and Wilson NJ. Efficacy of gabapentin in the management of pruritus of unknown origin. Arch Dermatol 141:1507-1509, 2005. (Pubitemid 41819025)
37. Ständer S, Weisshaar E, and Luger TA. Neurophysiological and neurochemical basis of modern pruritus treatment. Exp Dermatol 17:161-169, 2008. (Pubitemid 351233860)
38. González E, Sanguino RM, and Franco MA. Bupropion in atopic dermatitis. Pharmacopsychiatry 39:229, 2006. (Pubitemid 44899724)
39. Modell JG, Boyce S, Taylor E, and Katholi C. Treatment of atopic dermatitis and psoriasis vulgaris with bupropion-SR: A pilot study. Psychosom Med 64:835-840, 2002.
40. Dueñas-Laita A, Ruiz-Muñoz P, Armentia A, et al. Successful treatment of chronic drug-resistant urticaria with alprazolam. J Allergy Clin Immunol 123:504-505, 2009.